CRIS Current Research Information System

VENTURI, CLAUDIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.290
AS - Asia 3.007
EU - Europa 2.468
AF - Africa 197
SA - Sud America 183
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
Totale 9.153
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.252
VN - Vietnam 830
SG - Singapore 787
CN - Cina 733
GB - Regno Unito 642
IT - Italia 392
SE - Svezia 341
DE - Germania 321
HK - Hong Kong 209
FR - Francia 160
IN - India 142
RU - Federazione Russa 129
BR - Brasile 126
NL - Olanda 111
IE - Irlanda 84
ZA - Sudafrica 67
JP - Giappone 65
TG - Togo 58
EE - Estonia 51
CH - Svizzera 45
FI - Finlandia 44
UA - Ucraina 42
KR - Corea 38
JO - Giordania 35
BG - Bulgaria 31
NG - Nigeria 30
PH - Filippine 27
AR - Argentina 25
CA - Canada 23
CI - Costa d'Avorio 22
IR - Iran 20
IQ - Iraq 19
TH - Thailandia 19
BE - Belgio 17
BD - Bangladesh 15
PL - Polonia 13
AT - Austria 10
MX - Messico 10
TW - Taiwan 10
TR - Turchia 9
EC - Ecuador 8
LB - Libano 8
GR - Grecia 7
VE - Venezuela 7
ES - Italia 6
ID - Indonesia 6
SC - Seychelles 6
PK - Pakistan 5
SA - Arabia Saudita 5
TN - Tunisia 5
UZ - Uzbekistan 5
AU - Australia 4
CL - Cile 4
MY - Malesia 4
PE - Perù 4
PT - Portogallo 4
PY - Paraguay 4
QA - Qatar 4
RO - Romania 4
AE - Emirati Arabi Uniti 3
DK - Danimarca 3
KZ - Kazakistan 3
LT - Lituania 3
MA - Marocco 3
BO - Bolivia 2
CO - Colombia 2
CZ - Repubblica Ceca 2
EU - Europa 2
LV - Lettonia 2
OM - Oman 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
CR - Costa Rica 1
CY - Cipro 1
EG - Egitto 1
ET - Etiopia 1
HN - Honduras 1
IL - Israele 1
JM - Giamaica 1
KE - Kenya 1
KH - Cambogia 1
LY - Libia 1
MK - Macedonia 1
MT - Malta 1
RS - Serbia 1
SN - Senegal 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZW - Zimbabwe 1
Totale 9.153
Salva come PNG Salva come JPEG
Città #
Southend 597
Singapore 528
Ashburn 385
Chandler 357
Fairfield 258
Hong Kong 198
Ho Chi Minh City 174
San Jose 162
Beijing 160
Houston 159
Seattle 139
Woodbridge 139
Hanoi 135
Wilmington 135
Dong Ket 117
Princeton 116
Ann Arbor 110
Cambridge 87
Dublin 84
Boardman 79
Santa Clara 78
Bologna 72
New York 64
Lomé 58
Nanjing 56
Lauterbourg 55
Westminster 54
Tokyo 53
Padova 51
Hefei 45
Los Angeles 43
Bern 42
Medford 42
Amman 35
Frankfurt am Main 34
Helsinki 30
Sofia 30
Munich 29
Milan 28
Abeokuta 27
Redmond 27
Bremen 26
Hebei 26
Seoul 26
Jinan 24
Shenyang 24
Buffalo 23
Abidjan 22
Haiphong 22
Redondo Beach 22
Saint Petersburg 22
Berlin 21
Da Nang 21
San Diego 19
Jiaxing 18
São Paulo 18
Brussels 17
Falls Church 16
Johannesburg 16
Redwood City 16
Nanchang 15
Changsha 14
Guangzhou 14
Tianjin 14
Nuremberg 13
Shanghai 13
Baghdad 12
Orem 12
Tehran 11
Turin 11
Dallas 10
Florence 10
Mountain View 10
Turku 10
Zhengzhou 10
Atlanta 9
Falkenstein 9
Montreal 9
Norwalk 9
Paris 9
Rome 9
Toronto 8
Bangkok 7
Council Bluffs 7
Dearborn 7
Hải Dương 7
London 7
Ningbo 7
Phoenix 7
Warsaw 7
Amsterdam 6
Bengaluru 6
Bến Tre 6
Can Tho 6
Chengdu 6
Chicago 6
Fuzhou 6
Hangzhou 6
Shijiazhuang 6
Torino 6
Totale 5.828
Salva come PNG Salva come JPEG
Nome #
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 275
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 239
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 233
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 217
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 210
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 208
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 208
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 207
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 200
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 188
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 186
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 182
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients 180
Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing 179
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 176
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 174
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 172
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 171
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 170
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 168
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 162
An Italian Multicentre Study Using Different Digital PCR Instruments on BCR-ABL1 Positive Patients at Different Levels of CML Disease 161
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 159
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 158
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 158
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 157
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 156
COMPLEX GENETIC HETEROGENEITY INFLUENCES PROGNOSIS IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA NEGATIVE FOR RECURRENT FUSION GENES 155
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. 154
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 154
Evaluation of the Diasorin Q-Lamp technology for the molecular diagnosis of the philadelphia positive leukemias: an italian multicenter study 153
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 150
One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study 148
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 146
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 144
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets 144
Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients 144
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 141
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 140
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 140
Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome 139
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights 138
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse 138
SEVERAL FUSION TRANSCRIPTS ARE DETECTED BY NEXT GENERATION PAIRED END TRANSCRIPTOMIC RE-SEQUENCING APPROACH IN ADULT BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 138
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 138
Bcr-Abl kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the 2nd-generation TKI era 138
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 137
Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction 136
Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) 135
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 128
Molecular characterization of TP53 mutations in B-acute lymphoblastic leukemia (B-ALL) reveals missense substitutions, aberrant exon-junctions and intron retention events 125
Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies 125
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia 122
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 120
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 117
SET-UP OF A MULTIPLEX PCR TO RAPIDLY DETECT IKZF1 (IKAROS) GENE BREAKPOINT DELETION IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 115
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement 108
You have accessClinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters 97
null 76
Totale 9.337
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.934
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.934
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021358 0 0 0 0 0 0 0 0 0 31 44 283
2021/20221.082 98 19 58 86 123 71 11 49 56 88 195 228
2022/20231.300 153 197 49 177 107 112 34 81 207 26 85 72
2023/2024347 11 60 21 36 21 88 14 29 23 15 10 19
2024/20251.227 48 186 124 105 123 44 101 30 22 150 53 241
2025/20262.674 244 188 221 154 347 140 261 107 805 207 0 0
Totale 9.337